160 related articles for article (PubMed ID: 11583479)
1. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
Agrawal NG; Porras AG; Matthews CZ; Woolf EJ; Miller JL; Mukhopadhyay S; Neu DC; Gottesdiener KM
J Clin Pharmacol; 2001 Oct; 41(10):1106-10. PubMed ID: 11583479
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
Agrawal NG; Porras AG; Matthews CZ; Rose MJ; Woolf EJ; Musser BJ; Dynder AL; Mazina KE; Lasseter KC; Hunt TL; Schwartz JI; McCrea JB; Gottesdiener KM
J Clin Pharmacol; 2003 Mar; 43(3):268-76. PubMed ID: 12638395
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
Rodrigues AD; Halpin RA; Geer LA; Cui D; Woolf EJ; Matthews CZ; Gottesdiener KM; Larson PJ; Lasseter KC; Agrawal NG
Drug Metab Dispos; 2003 Feb; 31(2):224-32. PubMed ID: 12527704
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.
Birbara CA; Puopolo AD; Munoz DR; Sheldon EA; Mangione A; Bohidar NR; Geba GP;
J Pain; 2003 Aug; 4(6):307-15. PubMed ID: 14622687
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS.
Rose MJ; Agrawal N; Woolf EJ; Matuszewski BK
J Pharm Sci; 2002 Feb; 91(2):405-16. PubMed ID: 11835200
[TBL] [Abstract][Full Text] [Related]
6. Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Dallob A; Hawkey CJ; Greenberg H; Wight N; De Schepper P; Waldman S; Wong P; DeTora L; Gertz B; Agrawal N; Wagner J; Gottesdiener K
J Clin Pharmacol; 2003 Jun; 43(6):573-85. PubMed ID: 12817520
[TBL] [Abstract][Full Text] [Related]
7. Etoricoxib.
Cochrane DJ; Jarvis B; Keating GM
Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Patrignani P; Capone ML; Tacconelli S
Expert Opin Pharmacother; 2003 Feb; 4(2):265-84. PubMed ID: 12562317
[TBL] [Abstract][Full Text] [Related]
9. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Hunt RH; Harper S; Callegari P; Yu C; Quan H; Evans J; James C; Bowen B; Rashid F
Aliment Pharmacol Ther; 2003 Jan; 17(2):201-10. PubMed ID: 12534404
[TBL] [Abstract][Full Text] [Related]
10. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib.
Schwartz JI; Agrawal NG; Kher UA; DeSmet M; Cavanaugh PF; Guillaume M; Ebel DL; Merschman SA; Wagner JA
J Clin Pharmacol; 2007 Oct; 47(10):1342-6. PubMed ID: 17656618
[No Abstract] [Full Text] [Related]
12. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.
Hynninen VV; Olkkola KT; Neuvonen PJ; Laine K
Eur J Clin Pharmacol; 2009 Jan; 65(1):89-95. PubMed ID: 18777173
[TBL] [Abstract][Full Text] [Related]
13. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
Agrawal NG; Matthews CZ; Mazenko RS; Woolf EJ; Porras AG; Chen X; Miller JL; Michiels N; Wehling M; Schultz A; Gottlieb AB; Kraft WK; Greenberg HE; Waldman SA; Curtis SP; Gottesdiener KM
J Clin Pharmacol; 2004 Oct; 44(10):1125-31. PubMed ID: 15342613
[TBL] [Abstract][Full Text] [Related]
14. [Etoricoxib (Arcoxia)].
Leclercq P; Malaise MG
Rev Med Liege; 2004 May; 59(5):345-9. PubMed ID: 15270001
[TBL] [Abstract][Full Text] [Related]
15. The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants.
Schwartz J; Hunt T; Smith WB; Wong P; Larson P; Crumley T; Mehta A; Gottesdiener K; Agrawal N
J Clin Pharmacol; 2009 Jul; 49(7):807-15. PubMed ID: 19443681
[TBL] [Abstract][Full Text] [Related]
16. Safety of etoricoxib in patients with reactions to NSAIDs.
Quercia O; Emiliani F; Foschi FG; Stefanini GF
J Investig Allergol Clin Immunol; 2008; 18(3):163-7. PubMed ID: 18564626
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
Ikeda Y; Umemura K; Kondo K; Nakashima M; Kobayashi T; Takahashi M
Br J Clin Pharmacol; 2002 Nov; 54(5):453-62. PubMed ID: 12445023
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib.
Schwartz JI; Agrawal NG; Wehling M; Musser BJ; Gumbs CP; Michiels N; De Smet M; Wagner JA
Br J Clin Pharmacol; 2008 Dec; 66(6):811-7. PubMed ID: 18823299
[TBL] [Abstract][Full Text] [Related]
19. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].
Curtis SP; Bockow B; Fisher C; Olaleye J; Compton A; Ko AT; Reicin AS
BMC Musculoskelet Disord; 2005 Dec; 6():58. PubMed ID: 16321158
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects of etoricoxib: other considerations.
Kim JA; Choi YS; Kim SH
Mayo Clin Proc; 2005 Sep; 80(9):1233-4; author reply 1234. PubMed ID: 16178505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
